J.P. Morgan’s Salveen Richter Reiterates Buy on Teva, Citing TEV-408 Phase 2a Success and Pipeline-in-a-Product Potential
Tip Ranks·- JP Morgan analyst Salveen Richter reiterated a buy rating on Teva Pharmaceutical with a target price of 50.00 USD. - The rating is driven by the successful Phase 2a trial of TEV-408 in celiac disease, which showed significant intestinal protection without new safety issues. - Additional pipeline potential in vitiligo and upcoming catalysts further improve Teva's long-term growth prospects.